Deutsch English Français

Contact

EP2275103

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2275103

EP2275103 - mTOR inhibitors in the treatment of endocrine tumors [Right-click to bookmark this link]
Status	Patent revoked Status updated on 07.11.2018 Database last updated on 29.03.2025
Most recent event Tooltip	09.11.2018	Revocation of patent	published on 12.12.2018 [2018/50]
Applicant(s)	For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH
	[2011/03]
Inventor(s)	01 / Marks, Peter Wayne 145 Rimmon Road Woodbridge, CT 06525-1913 / US
	02 / Lebwohl, David 55 Pomeroy Road Madison, NJ 07940 / US
	[2014/17]
Former [2011/03]	01 / Marks, Peter Wayne 145 Rimmon Road Woodbridge, CT 06525-1913 / US
	02 / Lebwohl, David 55 Pomeroy Road Madison, NJ 07940 / US
Representative(s)	Marshall, Cameron John, et al Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB
	[N/P]
Former [2014/17]	Gruber, Markus, et al Novartis Pharma AG Patent Department 4002 Basel / CH
Former [2011/03]	Gruber, Markus, et al Novartis Pharma AG Patent Department CH-4002 Basel / CH
Application number, filing date	10175197.2	20.11.2006
	[2011/03]
Priority number, date	GB20050023658	21.11.2005 Original published format: GB 0523658
	GB20060001082	19.01.2006 Original published format: GB 0601082
	GB20060002747	10.02.2006 Original published format: GB 0602747
	GB20060007942	21.04.2006 Original published format: GB 0607942
	GB20060009272	10.05.2006 Original published format: GB 0609272
	GB20060009912	18.05.2006 Original published format: GB 0609912
	EP20060120660	14.09.2006 Original published format: EP 06120660
	[2011/03]
Previously filed application, date	EP20080162295	20.11.2006
	[2011/03]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	EP2275103
	Date:	19.01.2011
	Language:	EN
	[2011/03]
	Type:	A3 Search report
	No.:	EP2275103
	Date:	12.10.2011
	Language:	EN
	[2011/41]
	Type:	B1 Patent specification
	No.:	EP2275103
	Date:	23.04.2014
	Language:	EN
	[2014/17]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	08.09.2011
Classification	IPC:	A61K31/436, A61P35/00, A61P35/04, A61K38/31, A61K45/06	[2011/03]
	CPC:	A61K31/436 (EP,KR,NO,US); A61K38/31 (EP,US); A61K45/06 (EP,US); A61P25/00 (EP); A61P35/00 (EP,NO); A61P35/04 (EP); (+) A61P43/00 (EP) (-)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2011/03]
Extension states	HR	12.04.2012
Title	German:	mTOR-Inhibitoren in der Behandlung endokriner Tumore	[2011/03]
	English:	mTOR inhibitors in the treatment of endocrine tumors	[2011/03]
	French:	Inhibiteurs du mTOR pour le traitement des tumeurs endocriniennes	[2011/03]
Examination procedure	10.04.2012	Amendment by applicant (claims and/or description)
	12.04.2012	Examination requested [2012/21]
	20.07.2012	Despatch of a communication from the examining division (Time limit: M02)
	26.07.2012	Reply to a communication from the examining division
	13.08.2012	Despatch of a communication from the examining division (Time limit: M02)
	23.10.2012	Reply to a communication from the examining division
	22.01.2013	Despatch of a communication from the examining division (Time limit: M04)
	26.04.2013	Reply to a communication from the examining division
	20.11.2013	Despatch of a communication from the examining division (Time limit: M02)
	21.11.2013	Reply to a communication from the examining division
	09.01.2014	Communication of intention to grant the patent
	04.03.2014	Fee for grant paid
	04.03.2014	Fee for publishing/printing paid
Parent application(s) Tooltip	EP06819607.0 / EP1954269
	EP08162295.3 / EP2022498
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20060819607) is 16.06.2009
Opposition(s)	Opponent(s)	01 16.01.2015 27.01.2015 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street P.O. Box 3190 49131 Petah Tiqva / IL Opponent's representative Dörries, Hans Ulrich Df-mp Fünf Höfe Theatinerstrasse 16 80333 München / DE
		02 23.01.2015 28.01.2015 ADMISSIBLE Synthon B.V./Genthon B.V. Microweg 22 6545 CM Nijmegen / NL Opponent's representative Prins, Hendrik Willem Arnold & Siedsma Bezuidenhoutseweg 57 2594 AC The Hague / NL
		03 23.01.2015 28.01.2015 ADMISSIBLE Ethypharm 194 Bureaux de la Colline Bât D 92213 Saint-Cloud / FR Opponent's representative Allab, Myriam, et al, et al LLR 11 boulevard de Sébastopol 75001 Paris / FR
		04 23.01.2015 28.01.2015 ADMISSIBLE Maiwald GmbH Jungfernstieg 38 20354 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		05 23.01.2015 28.01.2015 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Albany Gate Darkes Lane Potters Bar Hertfordshire EN6 1AG / GB Opponent's representative Gilani, Anwar, et al, et al Venner Shipley LLP 406 Science Park Milton Road Cambridge CB4 0WW / GB
		[N/P]
	Former [2016/14]
	Opponent(s)	01 16.01.2015 27.01.2015 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street P.O. Box 3190 49131 Petah Tiqva / IL Opponent's representative Dörries, Hans Ulrich df-mp Fünf Höfe Theatinerstrasse 16 80333 München / DE
		02 23.01.2015 28.01.2015 ADMISSIBLE Synthon B.V./Genthon B.V. Microweg 22 6545 CM Nijmegen / NL Opponent's representative Prins, Hendrik Willem Arnold & Siedsma Bezuidenhoutseweg 57 2594 AC The Hague / NL
		03 23.01.2015 28.01.2015 ADMISSIBLE Ethypharm 194 Bureaux de la Colline Bât D 92213 Saint-Cloud / FR Opponent's representative Allab, Myriam, et al, et al LLR 11 boulevard de Sébastopol 75001 Paris / FR
		04 23.01.2015 28.01.2015 ADMISSIBLE Maiwald Patentanwalts GmbH Jungfernstieg 38 20354 Hamburg / DE Opponent's representative Hamm & Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		05 23.01.2015 28.01.2015 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Albany Gate Darkes Lane Potters Bar Hertfordshire EN6 1AG / GB Opponent's representative Gilani, Anwar, et al, et al Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge CB4 0WZ / GB
	Former [2015/10]
	Opponent(s)	01 16.01.2015 27.01.2015 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street P.O. Box 3190 49131 Petah Tiqva / IL Opponent's representative Dörries, Hans Ulrich df-mp Fünf Höfe Theatinerstrasse 16 80333 München / DE
		02 23.01.2015 28.01.2015 ADMISSIBLE Synthon B.V./Genthon B.V. Microweg 22 6545 CM Nijmegen / NL Opponent's representative Prins, Hendrik Willem Arnold & Siedsma Bezuidenhoutseweg 57 2594 AC The Hague / NL
		03 23.01.2015 28.01.2015 ADMISSIBLE Ethypharm 194 Bureaux de la Colline Bât D 92213 Saint-Cloud / FR Opponent's representative Allab, Myriam, et al, et al LLR 11 boulevard de Sébastopol 75001 Paris / FR
		04 23.01.2015 28.01.2015 ADMISSIBLE Maiwald Patentanwalts GmbH Jungfernstieg 38 20354 Hamburg / DE Opponent's representative Wittkopp, Alexander, et al, et al Maiwald Patentanwalts GmbH Jungfernstieg 38 20354 Hamburg / DE
		05 23.01.2015 28.01.2015 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Albany Gate Darkes Lane Potters Bar Hertfordshire EN6 1AG / GB Opponent's representative Gilani, Anwar, et al, et al Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge CB4 0WZ / GB
	Former [2015/09]
	Opponent(s)	01 16.01.2015 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street P.O. Box 3190 49131 Petah Tiqva / IL Opponent's representative Dörries, Hans Ulrich df-mp Fünf Höfe Theatinerstrasse 16 80333 München / DE
	deleted	Deletion: Legal effect of rejection of opposition [ N /P ]
	08.04.2015	Invitation to proprietor to file observations on the notice of opposition
	19.10.2015	Reply of patent proprietor to notice(s) of opposition
	12.05.2016	Date of oral proceedings
	28.06.2016	Despatch of minutes of oral proceedings
	28.06.2016	Date of despatch of rejection of opposition
	08.11.2017	Legal effect of revocation of patent [2018/50]
	12.10.2018	Despatch of communication that the patent will be revoked
Appeal following opposition	05.09.2016	Appeal received No. T1868/16
	08.11.2016	Statement of grounds filed
	08.11.2017	Result of appeal procedure: revocation of the patent
	25.08.2016	Appeal received No. T1868/16
	07.11.2016	Statement of grounds filed
	08.11.2017	Result of appeal procedure: revocation of the patent
	10.08.2016	Appeal received No. T1868/16
	07.11.2016	Statement of grounds filed
	08.11.2017	Result of appeal procedure: revocation of the patent
	01.09.2016	Appeal received No. T1868/16
	01.11.2016	Statement of grounds filed
	13.12.2016	Invitation to file observations in an appeal (Time limit: M02) [2016/51]
	08.11.2017	Result of appeal procedure: revocation of the patent
	08.11.2017	Date of oral proceedings
	14.11.2017	Minutes of the oral proceedings despatched
Fees paid	Renewal fee
	03.01.2011	Renewal fee patent year 03
	03.01.2011	Renewal fee patent year 04
	12.11.2010	Renewal fee patent year 05
	14.11.2011	Renewal fee patent year 06
	13.11.2012	Renewal fee patent year 07
	18.11.2013	Renewal fee patent year 08
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X]WO9747317 (CIBA GEIGY AG [CH], et al) [X] 1-12 * page 4, line 11 - page 5, line 6 * * page 14 * * page 15, paragraph l - page 17, paragraph 1 * * page 12, paragraph 3 * * page 14, paragraph 2 * * page 17, paragraph 5 - paragraph 6 *;
		[XY]WO02066019 (NOVARTIS AG [CH], et al) [X] 1-8,10-12 * page 1, paragraph 4 * * page 13, paragraph 3 * [Y] 9;
		[X]WO02080975 (WYETH CORP [US]) [X] 1-8,10-12 * abstract * * claim 2 * * claim 5 * * claim 14 * * page 16 * * claims 20-22 * * page 7, line 18 - line 21 *;
		[A]US2002183240 (GIBBONS JAMES J [US], et al) [A] 1 * claim 5 * * claim 32 *;
		[XY]WO02098416 (WYETH CORP [US]) [X] 1-8,10-12 * claim 1 * * claim 5 * * claim 10 * * claim 28 * * claim 29 * * claim 30 * [Y] 9;
		[Y]WO03020266 (WYETH CORP [US]) [Y] 1-8,10-12 * claim 5 * * page 2, paragraph 1 *;
		[XY]WO2004004644 (BETH ISRAEL HOSPITAL [US], et al) [X] 1-8,10-12 * claim 3 * * claims 14-15 * * claims 40-43 * [Y] 9;
		[A]US2004176339 (SHERMAN MATTHEW L [US], et al) [A] 1 * claim 7 *;
		[XY]WO2005080593 (NOVARTIS AG [CH], et al) [X] 1-8,10-12 * claims 8,9 * * page 10, paragraph 4 * * page 6, line 16 * [Y] 1-12;
		[XY]WO2005082411 (CHRISTENSEN JAMES G [US], et al) [X] 1-8,10-12 * page 2, paragraph 2 * * abstract * * claim 1 * * claim 9 * * claim 3 * * page 3, line 26 * * page 17, line 10 * * page 17, line 15 - line 16 * [Y] 9;
		[XP]WO2006065780 (NOVARTIS AG [CH], et al) [XP] 1-8,10-12* claim 23 *;
		[Y] - CANOBBIO L ET AL, "Use of long-acting somatostatin analog, lanreotide, in neuroendocrine tumors.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (199401), Database accession no. NLM21607321, XP002657696 [Y] 9 * abstract *
		[ ] - ONCOLOGY REPORTS JAN 1994 LNKD- PUBMED:21607321, (199401), vol. 1, no. 1, ISSN 1021-335X, pages 129 - 131
	Examination	- M. A. Kouvaraki, "Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas", Journal of Clinical Oncology, (20041013), vol. 22, no. 23, doi:10.1200/JCO.2004.04.024, ISSN 0732-183X, pages 4762 - 4771, XP055093883 DOI: http://dx.doi.org/10.1200/JCO.2004.04.024
		- James C. Yao ET AL, "Everolimus for Advanced Pancreatic Neuroendocrine Tumors", New England Journal of Medicine, (20110210), vol. 364, no. 6, doi:10.1056/NEJMoa1009290, ISSN 0028-4793, pages 514 - 523, XP055094009 DOI: http://dx.doi.org/10.1056/NEJMoa1009290
	by applicant	US4636505
		US4659516
		EP0296110
		US5010099
		WO9205179
		EP0520722
		EP0564409
		EP0566226
		WO9402136
		WO9402385
		WO9410202
		WO9503283
		WO9613273
		WO9630347
		WO9633980
		WO9702266
		EP0769947
		EP0787722
		WO9730034
		WO9738983
		WO9749688
		WO9800121
		WO9802441
		WO9808849
		WO9810767
		WO9811223
		EP0837063
		US5747498
		WO9822461
		WO9825929
		WO9835958
		WO9903854
		WO9917804
		WO9943653
		WO0009495
		WO0027820
		WO0027819
		WO0031247
		WO0037502
		WO0059509
		US6194181
		WO0114387
		WO0222577
		WO0238561
		WO03013541
		WO03064383
		WO03082859
		WO2004052359
		WO2004101583
		WO2005064343
		WO2005066156
		- BARAKAT ET AL., ENDOCRINE-RELATED CANCER, (2004), vol. 11, pages 1 - 18
		- TOMASSETTI ET AL., ANN ONCOL, (2001), vol. 12, no. 2, pages S95 - S99
		- WARNER RRP, GASTROENTEROLOGY, (2005), vol. 128, pages 1668 - 16842005
		- KULKE M., CANCER TREATMENT REVIEWS, (2003), vol. 29, pages 363 - 370
		- MODLIN 1M ET AL., GASTROENTEROLOGY, (2005), vol. 128, pages 1717 - 1751
		- DAVIS ET AL., GYNECOLOGY & OBSTETRICS, (1973), vol. 137, pages 637 - 644
		- JACOBSEN MB ET AL., EUR HEART J, (1995), vol. 16, pages 263 - 268
		- ARNOLD R; RINKE A ET AL., CLINICAL GASTROENTEROLOGY, (2005), vol. 19, no. 4, pages 649 - 656
		- M. PREWETT ET AL., CANCER RESEARCH, (1999), vol. 59, pages 5209 - 5218
		- F. YUAN ET AL., PROC. NATL. ACAD. SCI. USA, (199612), vol. 93, pages 14765 - 14770
		- Z. ZHU ET AL., CANCER RES., (1998), vol. 58, pages 3209 - 3214
		- J. MORDENTI ET AL., TOXICOLOGIC PATHOLOGY, (1999), vol. 27, no. 1, pages 14 - 21
		- M. S. O'REILLY ET AL., CELL, (1994), vol. 79, pages 315 - 328
	- M. S. O'REILLY ET AL., CELL, (1997), vol. 88, pages 277 - 285
	Opposition	- "How to Edit Your Study Record", URL: https: / /clinicaltrials.gov/ct2 /manage-recs /how-edit
		- "How to Register Your Study", URL: https: //clinicatrials.gov/ct2/manage-recs /how- register#ClinicalTrialsRecordReview

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.32; 35p